% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Capper:186735,
      author       = {D. Capper$^*$ and G. Reifenberger$^*$ and P. J. French and
                      L. Schweizer$^*$ and M. Weller and M. Touat and S. P. Niclou
                      and P. Euskirchen and C. Haberler and M. E. Hegi and S.
                      Brandner and E. Le Rhun and R. Rudà and M. Sanson and G.
                      Tabatabai$^*$ and F. Sahm$^*$ and P. Y. Wen and P. Wesseling
                      and M. Preusser and M. J. van den Bent},
      title        = {{EANO} guideline on rational molecular testing of gliomas,
                      glioneuronal and neuronal tumors in adults for targeted
                      therapy selection.},
      journal      = {Neuro-Oncology},
      volume       = {25},
      number       = {5},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2023-00087},
      pages        = {813-826},
      year         = {2023},
      note         = {2023 May 4;25(5):813-826},
      abstract     = {The mainstay of treatment for adult patients with gliomas,
                      glioneuronal and neuronal tumors consists of combinations of
                      surgery, radiotherapy and chemotherapy. For many systemic
                      cancers, targeted treatments are a part of standard of care,
                      however the predictive significance of most of these targets
                      in CNS tumors remains less well studied. Despite that, there
                      is an increasing use of advanced molecular diagnostics that
                      identify potential targets, and tumor agnostic regulatory
                      approvals on targets also present in CNS tumors have been
                      granted. This raises the question when and for which targets
                      it is meaningful to test in adult patients with CNS tumors.
                      This evidence based guideline reviews the evidence available
                      for targeted treatment for alterations in the RAS/MAPK
                      pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK,
                      FGFR, NTRK, PDGFRA, ROS1), in cell cycle signaling (CDK4/6,
                      MDM2/4, TSC1/2) and altered genomic stability (mismatch
                      repair, POLE, high TMB, HRD) in adult patients with gliomas,
                      glioneuronal and neuronal tumors. At present, targeted
                      treatment for BRAF p.V600E alterations is to be considered
                      part of standard of care for patients with recurrent
                      gliomas, pending regulatory approval. For approved tumor
                      agnostic treatments for NTRK fusions and high TMB, the
                      evidence for efficacy in adult patients with CNS tumors is
                      very limited, and treatment should preferably be given
                      within prospective clinical registries and trials. For
                      targeted treatment of CNS tumors with FGFR fusions or
                      mutations, clinical trials are ongoing to confirm modest
                      activity so far observed in basket trials. For all other
                      reviewed targets, evidence of benefit in CNS tumors is
                      currently lacking, and testing/treatment should be in the
                      context of available clinical trials.},
      keywords     = {Adults (Other) / EANO (Other) / Glioma (Other) / Guideline
                      (Other) / Targeted treatments (Other)},
      cin          = {BE01 / FM01 / TU01 / HD01 / ED01 / B300},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331 / I:(DE-He78)FM01-20160331 /
                      I:(DE-He78)TU01-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)ED01-20160331 / I:(DE-He78)B300-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36632791},
      doi          = {10.1093/neuonc/noad008},
      url          = {https://inrepo02.dkfz.de/record/186735},
}